Literature DB >> 2848172

Experimental demyelination induced by coronavirus JHM (MHV-4): molecular identification of a viral determinant of paralytic disease.

J O Fleming1, M D Trousdale, J Bradbury, S A Stohlman, L P Weiner.   

Abstract

The molecular basis for demyelination induced by the neurotropic murine coronavirus JHM (JHMV or MHV4) is unknown. We have attempted to explore this issue by using neutralizing monoclonal antibodies specific for the major JHMV glycoprotein (E2) to select sets of neutralization resistant (NR) antigenic variant viruses. Monoclonal antibodies J.7.2 and J.2.2 bind to topographically distinct sites on E2. NR variants selected with J.7.2, like parental JHMV, predominantly cause a fatal encephalitis when given intracerebrally to mice, while J.2.2-selected NR variants cause a subacute disease characterized by paralysis and severe demyelination. We report here that consecutive selection with both J.2.2 and J.7.2 monoclonal antibodies results in NR variants which are markedly attenuated in both encephalitic potential and ability to induce demyelination. Analysis of the different variants suggests that the subregion of E2 bound by monoclonal antibody J.7.2 may be a critical viral determinant of paralysis and demyelination in this model system.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2848172      PMCID: PMC7134751          DOI: 10.1016/0882-4010(87)90033-7

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  32 in total

1.  Recombination between nonsegmented RNA genomes of murine coronaviruses.

Authors:  M M Lai; R S Baric; S Makino; J G Keck; J Egbert; J L Leibowitz; S A Stohlman
Journal:  J Virol       Date:  1985-11       Impact factor: 5.103

2.  Hemagglutinin-neuraminidase glycoprotein as a determinant of pathogenicity in mumps virus hamster encephalitis: analysis of mutants selected with monoclonal antibodies.

Authors:  A Löve; R Rydbeck; K Kristensson; C Orvell; E Norrby
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

3.  Pathogenesis of demyelination induced by a mouse hepatitis.

Authors:  L P Weiner
Journal:  Arch Neurol       Date:  1973-05

4.  Antigenic drift in influenza A/USSR/90/77(H1N1) variants selected in vitro with monoclonal antibodies.

Authors:  S Nakajima; A P Kendal
Journal:  Virology       Date:  1981-09       Impact factor: 3.616

5.  Amino acid sequence changes in antigenic variants of type A influenza virus N2 neuraminidase.

Authors:  W G Laver; G M Air; R G Webster; L J Markoff
Journal:  Virology       Date:  1982-10-30       Impact factor: 3.616

6.  Proteolytic cleavage of peplomeric glycoprotein E2 of MHV yields two 90K subunits and activates cell fusion.

Authors:  L S Sturman; K V Holmes
Journal:  Adv Exp Med Biol       Date:  1984       Impact factor: 2.622

7.  Animal models of multiple sclerosis.

Authors:  J O Fleming
Journal:  Mayo Clin Proc       Date:  1985-07       Impact factor: 7.616

8.  Site-specific alteration of murine hepatitis virus type 4 peplomer glycoprotein E2 results in reduced neurovirulence.

Authors:  R G Dalziel; P W Lampert; P J Talbot; M J Buchmeier
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

9.  Chronic central nervous system demyelination in mice after JHM virus infection.

Authors:  S A Stohlman; L P Weiner
Journal:  Neurology       Date:  1981-01       Impact factor: 9.910

10.  Virus persistence and recurring demyelination produced by a temperature-sensitive mutant of MHV-4.

Authors:  R L Knobler; P W Lampert; M B Oldstone
Journal:  Nature       Date:  1982-07-15       Impact factor: 49.962

View more
  37 in total

1.  Role of viral persistence in retaining CD8(+) T cells within the central nervous system.

Authors:  N W Marten; S A Stohlman; C C Bergmann
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Control of central nervous system viral persistence by neutralizing antibody.

Authors:  Chandran Ramakrishna; Cornelia C Bergmann; Roscoe Atkinson; Stephen A Stohlman
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

3.  T-cell-mediated clearance of mouse hepatitis virus strain JHM from the central nervous system.

Authors:  M A Sussman; R A Shubin; S Kyuwa; S A Stohlman
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

4.  Characterization of mouse hepatitis virus-specific cytotoxic T cells derived from the central nervous system of mice infected with the JHM strain.

Authors:  S A Stohlman; S Kyuwa; J M Polo; D Brady; M M Lai; C C Bergmann
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

5.  Axonal damage is T cell mediated and occurs concomitantly with demyelination in mice infected with a neurotropic coronavirus.

Authors:  A A Dandekar; G F Wu; L Pewe; S Perlman
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

6.  Evolution of mouse hepatitis virus: detection and characterization of spike deletion variants during persistent infection.

Authors:  C L Rowe; S C Baker; M J Nathan; J O Fleming
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

7.  Induction of self-reactive T cells after murine coronavirus infection.

Authors:  S Kyuwa; K Yamaguchi; Y Toyoda; K Fujiwara
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

8.  De novo recruitment of antigen-experienced and naive T cells contributes to the long-term maintenance of antiviral T cell populations in the persistently infected central nervous system.

Authors:  Jingxian Zhao; Jincun Zhao; Stanley Perlman
Journal:  J Immunol       Date:  2009-09-28       Impact factor: 5.422

9.  Cytokine induction during T-cell-mediated clearance of mouse hepatitis virus from neurons in vivo.

Authors:  B D Pearce; M V Hobbs; T S McGraw; M J Buchmeier
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

10.  Restricted virus replication in the spinal cords of nude mice infected with a Theiler's virus variant.

Authors:  A Zurbriggen; M Yamada; C Thomas; R S Fujinami
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.